A 63-year-old male patient with stage IV lung adenocarcinoma displaying EGFR 19 deletion (case NCCLu-263) received erlotinib as the first-line treatment (Figure 4A–D). The gene discussed is EGFR; the disease is lung adenocarcinoma.